Mixed Results for Adjuvant Pembro in Endometrial Cancer

Adding adjuvant pembrolizumab to chemotherapy only led to a benefit in patients with mismatch repair-deficient high-risk endometrial cancers, a phase 3 trial found.
Medscape Medical News

source https://www.medscape.com/viewarticle/adjuvant-pembrolizumab-endometrial-cancer-disappointing-yet-2024a1000h0l?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?